Trial Outcomes & Findings for Interactive Voice Response Telephone Technology for the Treatment of Smoking in Patients With Heart Disease (NCT NCT00449852)

NCT ID: NCT00449852

Last Updated: 2026-06-30

Results Overview

Self-reported abstinence from any tobacco product during the time period.

Recruitment status

COMPLETED

Study phase

Target enrollment

440 participants

Primary outcome timeframe

Baseline to 26 weeks

Results posted on

2026-06-30

Participant Flow

Participant milestones

Participant milestones
Measure	Interactive Voice Response Group Participants received automated telephone calls at Days 3, 14, 30, 30, 90, 120, 150, and 180 after hospitalization in addition to the in-hospital counseling with a trained nurse counsellor with a standardized flowsheet and written smoking cessation information.	Usual Care Group Participants received in-hospital counseling from a trained nurse-coordinator, guided by a standardized flowsheet and were provided written information about smoking cessation.
Overall Study STARTED	216	224
Overall Study Analyzed	200	210
Overall Study COMPLETED	95	100
Overall Study NOT COMPLETED	121	124

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Participants who died or moved to an untraceable address during treatment were removed from analysis.

Baseline characteristics by cohort

PRIMARY outcome

Timeframe: Baseline to 26 weeks

Self-reported abstinence from any tobacco product during the time period.

Outcome measures

Outcome measures
Measure	Interactive Voice Response Group n=200 Participants Participants received automated telephone calls at Days 3, 14, 30, 30, 90, 120, 150, and 180 after hospitalization in addition to the in-hospital counseling with a trained nurse counsellor with a standardized flowsheet and written smoking cessation information.	Usual Care Group n=210 Participants Participants received in-hospital counseling from a trained nurse-coordinator, guided by a standardized flowsheet and were provided written information about smoking cessation.
Continuous Abstinence Rate	38 Percentage	29.5 Percentage

SECONDARY outcome

Timeframe: 27 to 52 weeks

Self-reported abstinence from any tobacco product during the time period.

Outcome measures

Outcome measures
Measure	Interactive Voice Response Group n=200 Participants Participants received automated telephone calls at Days 3, 14, 30, 30, 90, 120, 150, and 180 after hospitalization in addition to the in-hospital counseling with a trained nurse counsellor with a standardized flowsheet and written smoking cessation information.	Usual Care Group n=210 Participants Participants received in-hospital counseling from a trained nurse-coordinator, guided by a standardized flowsheet and were provided written information about smoking cessation.
Continuous Abstinence Rate	34.5 Percentage	28.6 Percentage

SECONDARY outcome

Timeframe: At weeks 26 and 52.

no smoking (not even a puff) in the preceding 7 days

Outcome measures

Outcome measures
Measure	Interactive Voice Response Group n=200 Participants Participants received automated telephone calls at Days 3, 14, 30, 30, 90, 120, 150, and 180 after hospitalization in addition to the in-hospital counseling with a trained nurse counsellor with a standardized flowsheet and written smoking cessation information.	Usual Care Group n=210 Participants Participants received in-hospital counseling from a trained nurse-coordinator, guided by a standardized flowsheet and were provided written information about smoking cessation.
7-day Point-prevalence Abstinence Rates at 26 weeks	42 Precentage	36.2 Precentage
7-day Point-prevalence Abstinence Rates at 52 weeks	40.0 Precentage	33.3 Precentage

Adverse Events

Interactive Voice Response Group

Serious events: 0 serious events

Other events: 0 other events

Deaths: 6 deaths

Usual Care Group

Serious events: 0 serious events

Other events: 0 other events

Deaths: 5 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Robert Reid

University of Ottawa Heart Institute

Phone: 6136967000

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Measure	Interactive Voice Response Group n=200 Participants Participants received automated telephone calls at Days 3, 14, 30, 30, 90, 120, 150, and 180 after hospitalization in addition to the in-hospital counseling with a trained nurse counsellor with a standardized flowsheet and written smoking cessation information.	Usual Care Group n=210 Participants Participants received in-hospital counseling from a trained nurse-coordinator, guided by a standardized flowsheet and were provided written information about smoking cessation.	Total n=410 Participants Total of all reporting groups
Age, Continuous	53.9 Years STANDARD_DEVIATION 8.4 • n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	54.6 Years STANDARD_DEVIATION 9.4 • n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	54.2 Years STANDARD_DEVIATION 8.9 • n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.
Sex: Female, Male Female	47 Participants n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	58 Participants n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	105 Participants n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.
Sex: Female, Male Male	153 Participants n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	152 Participants n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	305 Participants n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.
Race and Ethnicity Not Collected	—	—	0 Participants Race and Ethnicity were not collected from any participant.
Highest level of education completed Postsecondary	93 Participants n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	101 Participants n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	194 Participants n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.
Highest level of education completed High school	100 Participants n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	90 Participants n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	190 Participants n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.
Highest level of education completed Primary school	7 Participants n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	19 Participants n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	26 Participants n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.
Reason for hospital admission Acute coronary syndrome	122 Participants n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	132 Participants n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	254 Participants n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.
Reason for hospital admission Diagnostic catheterization	52 Participants n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	48 Participants n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	100 Participants n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.
Reason for hospital admission Percutaneous coronary intervention	14 Participants n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	16 Participants n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	30 Participants n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.
Reason for hospital admission Coronary artery bypass grafting	12 Participants n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	14 Participants n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	26 Participants n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.
Cigarettes per day </= 10	31 Participants n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	33 Participants n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	64 Participants n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.
Cigarettes per day 11-20	65 Participants n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	72 Participants n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	137 Participants n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.
Cigarettes per day 21-30	84 Participants n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	78 Participants n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	162 Participants n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.
Cigarettes per day 31+	19 Participants n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	26 Participants n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	45 Participants n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.
Cigarettes per day Unknown	1 Participants n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	1 Participants n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	2 Participants n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.
Fagerstrom score for nicotine dependence	5.2 score STANDARD_DEVIATION 2.2 • n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	5.1 score STANDARD_DEVIATION 2.2 • n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	5.1 score STANDARD_DEVIATION 2.2 • n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.
Ready to quit within next 30 days	188 Participants n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	203 Participants n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	391 Participants n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.
Received cost-free NRT	67 Participants n=200 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	74 Participants n=210 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.	141 Participants n=410 Participants • Participants who died or moved to an untraceable address during treatment were removed from analysis.